Alumis (ALMS) Competitors $4.70 -0.22 (-4.47%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$4.57 -0.13 (-2.77%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. AVBP, ORGO, CRON, CVAC, GHRS, NUVB, CRMD, IMNM, ABUS, and BCYCShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include ArriVent BioPharma (AVBP), Organogenesis (ORGO), Cronos Group (CRON), CureVac (CVAC), GH Research (GHRS), Nuvation Bio (NUVB), CorMedix (CRMD), Immunome (IMNM), Arbutus Biopharma (ABUS), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Alumis vs. ArriVent BioPharma Organogenesis Cronos Group CureVac GH Research Nuvation Bio CorMedix Immunome Arbutus Biopharma Bicycle Therapeutics ArriVent BioPharma (NASDAQ:AVBP) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Does the media refer more to AVBP or ALMS? In the previous week, Alumis had 19 more articles in the media than ArriVent BioPharma. MarketBeat recorded 36 mentions for Alumis and 17 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.88 beat Alumis' score of 0.32 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 3 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, AVBP or ALMS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$2.57-7.23AlumisN/AN/AN/AN/AN/A Do insiders & institutionals have more ownership in AVBP or ALMS? 9.5% of ArriVent BioPharma shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is AVBP or ALMS more profitable? Alumis' return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Alumis N/A N/A N/A Do analysts rate AVBP or ALMS? ArriVent BioPharma presently has a consensus price target of $39.00, suggesting a potential upside of 110.02%. Alumis has a consensus price target of $26.00, suggesting a potential upside of 453.19%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the MarketBeat Community prefer AVBP or ALMS? ArriVent BioPharma received 1 more outperform votes than Alumis when rated by MarketBeat users. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes21100.00% Underperform VotesNo VotesAlumisOutperform Votes20100.00% Underperform VotesNo Votes SummaryAlumis beats ArriVent BioPharma on 7 of the 10 factors compared between the two stocks. Remove Ads Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$221.94M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E RatioN/A7.2023.1719.03Price / SalesN/A226.01385.1993.17Price / CashN/A65.6738.1634.64Price / BookN/A6.476.944.33Net IncomeN/A$141.90M$3.20B$247.06M7 Day Performance25.33%-3.20%-2.29%-0.37%1 Month Performance1.08%-5.64%2.88%-3.85%1 Year PerformanceN/A-7.47%10.82%1.27% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumisN/A$4.70-4.5%$26.00+453.2%N/A$221.94MN/A0.00N/AAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeAVBPArriVent BioPharma1.4346 of 5 stars$20.21+3.5%$39.00+93.0%+3.2%$687.46MN/A-7.8640ORGOOrganogenesis3.5813 of 5 stars$5.42+11.1%$5.50+1.5%+69.2%$687.41M$482.04M-90.33950CRONCronos Group1.9068 of 5 stars$1.87+4.2%$3.00+60.9%-32.2%$684.73M$117.62M-14.35450CVACCureVac3.9857 of 5 stars$3.00+3.8%$10.00+233.3%-8.2%$671.64M$543.28M5.45880News CoverageGHRSGH Research2.5021 of 5 stars$12.80+2.4%$30.86+141.2%+14.4%$665.70MN/A-16.2010NUVBNuvation Bio2.0445 of 5 stars$1.96+3.4%$8.33+326.3%-52.7%$662.12M$7.87M-0.9060Analyst ForecastCRMDCorMedix2.6347 of 5 stars$10.77-1.3%$16.00+48.6%+61.3%$653.49M$12.26M-13.3030Earnings ReportAnalyst ForecastOptions VolumeNews CoverageIMNMImmunome1.9533 of 5 stars$8.15-0.4%$25.50+212.9%-71.5%$650.18M$10.13M-1.0040Insider TradeNews CoverageGap UpABUSArbutus Biopharma1.4613 of 5 stars$3.39+3.4%$5.50+62.2%+25.8%$642.38M$6.74M-7.8890Earnings ReportAnalyst RevisionNews CoverageBCYCBicycle Therapeutics1.9498 of 5 stars$9.20+1.3%$29.14+216.8%-62.6%$636.66M$35.28M-2.80240High Trading Volume Remove Ads Related Companies and Tools Related Companies AVBP Alternatives ORGO Alternatives CRON Alternatives CVAC Alternatives GHRS Alternatives NUVB Alternatives CRMD Alternatives IMNM Alternatives ABUS Alternatives BCYC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
